

Statement of Cash Flows -

Peptinovo Biopharma Inc

January 1-December 31, 2023

FULL NAME	TOTAL
OPERATING ACTIVITIES	
Net Income	-2,832,689.52
Adjustments to reconcile Net Income to Net Cash provided by operations:	
20000 Accounts Payable	10,943.72
Credit card old	-14,451.63
Direct Deposit Payable	
Loan Cantilever	
Loan Ehlert	
Loan Homan 10	
Loan Stinson	
Loan Tokarz	
Patents	-11,078.18
Payroll Liabilities:Federal Taxes (941/944)	813.79
Payroll Liabilities:Federal Unemployment (940)	
Payroll Liabilities:MI Income Tax	-498.27
Payroll Liabilities:MI Unemployment Tax	173.22
Total for Adjustments to reconcile Net Income to Net Cash provided by operations:	-\$14,097.35
Net cash provided by operating activities	-\$2,846,786.87
INVESTING ACTIVITIES	0
FINANCING ACTIVITIES	
30100 Stock	450.00
Convertible Debt/Bridge 2022	3,013,400.00
SAFE Series 1	123,700.00
Net cash provided by financing activities	\$3,137,550.00
NET CASH INCREASE FOR PERIOD	\$290,763.13
Cash at beginning of period	\$59,735.12
CASH AT END OF PERIOD	\$350,498.25